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An oncogenic role for the ubiquitin ligase UBE2O 
by targeting AMPK-α2 for degradation 
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There has been controversy regarding the role of AMPK in cancer, some of which may be due to 
functional differences between isoforms. In this issue of Cancer Cell, Vila et al report that UBE2O, 
a ubiquitin ligase over-expressed in some human cancers, specifically triggers the ubiquitination 
and degradation of AMPK-α2. 
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AMP-activated protein kinase (AMPK) is a cellular energy sensor involved in matching the supply 
of ATP from catabolism to the demand created by anabolism and other ATP-consuming activities, 
including cell division (Ross et al., 2016). As soon as demand out-strips supply the ADP:ATP ratio 
will increase, and this is amplified by the adenylate kinase reaction (2ADP  ↔ ATP + AMP) into 
even larger increases in AMP:ATP ratios. Increases in ADP and AMP switch on AMPK by three 
complementary mechanisms, all antagonized by ATP: binding of AMP or ADP (i) promotes 
phosphorylation of Thr172 in the activation loop of AMPK by the upstream kinase, and (ii) inhibits 
Thr172 dephosphorylation, thus activating AMPK; while (iii) binding of AMP causes further 
allosteric activation of the phosphorylated kinase. AMPK then attempts to restore cellular energy 
homeostasis by switching on alternate catabolic pathways that generate ATP (especially the more 
energy-efficient oxidative pathways, rather than the glucose-hungry glycolysis), while switching off 
most ATP-consuming processes. The latter include protein synthesis, switched off indirectly by 
inactivation of mTOR complex-1 (Gwinn et al., 2008), and progress through the cell cycle, which is 
arrested in G1 phase (Fogarty et al., 2016). 
 The principal kinase phosphorylating Thr172, which is required for AMPK activation during 
energy stress although not directly activated by it, is LKB1. LKB1 was originally identified as a 
tumor suppressor mutated in an inherited susceptibility to cancer, Peutz-Jeghers syndrome, and was 
subsequently shown to be mutated in many sporadic cancers, especially lung adenocarcinomas. 
Since AMPK inhibits cell growth and proliferation, at first it seemed obvious that AMPK exerted 
the tumour suppressor effects of LKB1. However, this simple picture has recently become much 
more confused. The catalytic subunit of AMPK exists as two isoforms, α1 and α2 (Ross et al., 
2016). While α2 knockout mouse embryo fibroblasts (MEFs) are sensitive to transformation by 
mutant H-Ras in vitro, and H-Ras-transformed α2-KO cells grow even more rapidly than wild type 
controls as tumors in vivo (correlating with reduced expression of p53), α1-KO MEFs are resistant 
to transformation in vitro and grow very poorly in vivo (Phoenix et al., 2012). In addition, in a 
synthetic lethal screen that searched for genes required for growth of cells over-expressing Myc, 
one of the hits was PRKAA1, encoding AMPK-α1 (Liu et al., 2012). Taken together, these results 
suggest that while AMPK-α2 might indeed be a tumor suppressor, AMPK-α1 might be an 
oncoprotein that promotes the survival of tumor cells, possibly by protecting them under conditions 
of energy stress. Consistent with this, recent analyses of the human cancer genome databases 
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revealed that while the PRKAA2 gene (encoding α2) is quite often mutated in human cancers, 
PRKAA1 tends to be amplified instead (Monteverde et al., 2015; Ross et al., 2016). 
 Vila et al (2017) were interested in the role of UBE2O, a large ubiquitin ligase with both E2 and 
E3 activities. UBE2O is located within a chromosomal region (17q25) that is amplified in some 
human cancers. They first generated Ube2o knockout mice, and found that MEFs derived from 
these grew more slowly and were more resistant to transformation in vitro than wild type controls, 
while UBE2O over-expression had the opposite effects. By crossing Ube2O knockout mice with 
two genetically engineered mouse models of breast and prostate cancer, they found that the 
severities of the lesions were greatly reduced in the homozygous knockouts, with intermediate 
effects in heterozygotes. 
 To pinpoint downstream targets of UBE2O responsible for these effects, they identified 
interacting proteins by mass spectrometry, among which AMPK-α2 was particularly prominent. In 
cell-free assays, UBE2O could trigger K48-linked polyubiquitylation of AMPK-α2 in the presence 
of an E1. Of three previously predicted ubiquitylation sites on α2, only mutation of Lys470 in the 
C-terminal domain abolished the modification. Interestingly, Lys470 is conserved in α2 isoforms 
from other vertebrates, but is replaced by arginine in α1 isoforms. Consistent with the idea that 
K48-linked polyubiquitylation of α2 triggers its degradation, RNAi knockdown of UBE2O in 
HCT116 human colon carcinoma cells increased the stability of α2 but not α1, and also increased 
the phosphorylation of two AMPK targets, acetyl-CoA carboxylase (ACC) and Raptor, the latter a 
key component of the mTORC1 complex. Knockdown of α2, but not α1, reversed growth 
inhibition induced by UBE2O knockdown in HCT116 cells grown as mouse xenografts, while 
knockout of α2 but not α1 by CRISPR/Cas9 in a human haploid cancer cell line (HAP1) reversed 
both inhibition of growth and increased phosphorylation of AMPK targets induced by UBE2O 
knockdown.  The authors also provided evidence that UBE2O depletion reprograms cells away 
from glycolysis towards oxidative metabolism, and that this was dependent on AMPK-α2. To 
demonstrate the applicability of the results to humans, they found an inverse correlation between 
expression of UBE2O and AMPK-α2, but not –α1, in breast cancer biopsies by 
immunohistochemistry. Finally, UBE2O has previously been shown to be potently inhibited by 
arsenite, which is currently undergoing clinical trials in several cancers. Supporting the idea that 
arsenite might be effective in part via inhibition of UBE2O, treatment of their breast and prostate 
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cancer mouse models with arsenite in vivo reduced the severity of the lesions to a similar extent as 
UBE2O deletion. 
 The results of Vila et al (2017) therefore fully support the idea that AMPK-α2 is a tumor 
suppressor. They not only identify the first downstream target for UBE2O, but also the first 
ubiquitin ligase that seems to specifically target AMPK-α2 for degradation. Interestingly, UBE2O  
(originally known as E2-230) is expressed particularly highly in reticulocytes, and was proposed to 
have a role in degradation of proteins that are absent from the erythrocytes that develop from them 
(Wefes et al., 1995), one of which is AMPK-α2 (Foretz et al., 2011). Aberrant amplification of 
chromosomal region 17q25 may, however, lead to over-expression of UBE2O in cancer cells 
derived from other cell types, causing increased degradation of AMPK-α2 that might then promote 
the more glycolytic metabolism typical of tumor cells, while reducing expression of the tumor 
suppressor p53. 
 The idea that AMPK-α2 is a tumor suppressor, while AMPK-α1 is a tumor promoter, is 
superficially attractive, but it is already clear that this is an over-simplification. Pineda et al (2015) 
reported that the melanoma antigens MAGE-A3/-A6 recruit the ubiquitin ligase TRIM28 to 
AMPK-α1 and triggers its degradation. MAGE-A3/-A6 are closely related tumour antigens that are 
normally only expressed in testis, but are aberrantly re-expressed in some tumors. By triggering 
polyubiquitylation and proteasomal degradation of AMPK-α1, MAGE-A3/-A6 appear to promote 
tumor formation. This story has obvious echoes of the role of UBE2O in reticulocytes and in 
cancer, except that the AMPK isoform affected is α1 rather than α2. Clearly, it remains a challenge 
to fully understand the context-dependent roles of α1 and –α2 in different cancers. 
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Figure: Normal role of UBE2O in erythrocytes, and aberrant role in cancer. UBE2O is 
highly expressed in reticulocytes, where its role may be to remove proteins not found in 
mature erythrocytes, including AMPK-α2. However, amplification of UBE2O in some 
tumors also leads to degradation of AMPK-α2, conferiing growth advantages on the 
tumor cells. 
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